Constipation and multimorbidity: a pediatrician's view
DOI: 10.32364/2618-8430-2024-7-1-11
A.A. Nizhevich1, D.S. Valeeva2, V.V. Loginovskaya2
1Bashkir State Medical University, Ufa, Russian Federation
2Russian Children's Clinical Hospital, Ufa, Russian Federation
The prevalence of constipation among the Russian child population is extremely high. Chronic constipation is a classic example of a multimorbidity and has significant, including disabling, consequences for the child's health. The syndrome of increased intestinal permeability, which occurs with chronic constipation, forms a whole block of systemic pathology involving almost all human systems and organs. More than half (51.7%) of children with chronic constipation have symptoms of chronic fecal intoxication. The article highlights the etiopathogenetic aspects of the increased intestinal permeability in patients with chronic constipation. The article also discusses the association of intestinal motility disorders with the development of dermatosis, urinary tract pathology, allergic, mental and other diseases. The butyrate role as a key molecule of intestinal metabolism is considered. The importance of lactitol in the constipation treatment and increased intestinal permeability correction is also shown. This drug has a complex effect: during its use, there is an increase in the bowel movement frequency, a decrease in the constipation symptoms, as well as the regulation of the intestinal barrier to protect the body from the constipation effects.
Keywords: increased intestinal permeability, constipation, multimorbidity, short-chain fatty acids, butyrate, laxative, lactitol.
For citation: Nizhevich A.A., Valeeva D.S., Loginovskaya V.V. Constipation and multimorbidity: a pediatrician's view. Russian Journal of Woman and Child Health. 2024;7(1):71–78 (in Russ.). DOI: 10.32364/2618-8430-2024-7-1-11.
About the authors:
Alexander A. Nizhevich — Dr. Sc. (Med.), Professor of the Department of Hospital Pediatrics, Bashkir State Medical University; 3, Lenin str., Ufa, 450008, Russian Federation; ORCID iD 0000-0002-7408-5719.
Diana S. Valeeva — Chief Consultant Pediatric Gastroenterologists of the Ministry of Health of the Republic of Bashkortostan, Deputy Chief Medical Officer for Medical Affairs; Russian Children's Clinical Hospital; 98, Stepan Kuvykin str., Ufa, 450106, Russian Federation; ORCID iD 0000-0002-4421-0005.
Valentina V. Loginovskaya — allergologist, Russian Children's Clinical Hospital; 98, Stepan Kuvykin str., Ufa, 450106, Russian Federation.
Contact information: Alexander A. Nizhevich, e-mail: aanj@ya.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 01.12.2023.
Revised 22.12.2023.
Accepted 19.01.2024.
References
1. Алхасов А.Б., Батаев С.М., Бельмер С.В. и др. Детская гастроэнтерология. Национальное руководство. М.: ГЭОТАР-Медиа; 2022. [Alkhasov A.B., Batayev S.M., Bel'mer S.V. et al. Children's gastroenterology. National leadership. M.: GEOTAR-Media; 2022 (in Russ.)].
2. Hyams J.S., di Lorenzo C., Saps M. et al. Childhood functional gastrointestinal disorders: child / adolescent. Gastroenterology. 2016:150(6):1456–1468.e2. DOI: 10.1053/j.gastro.2016.02.015.
3. Эрдес С.И., Мацукатова Б.О., Ревякина С.А. Запоры у детей (результаты нового российского популяционного исследования). РМЖ. 2011;3:159–164. [Erdes S.I., Matsukatova B.O., Revyakina S.A. Constipation in children (results of a new Russian population study). RMJ. 2011;3:159–164 (in Russ.)].
4. Бельмер С.В., Волынец Г.В., Горелов А.В. и др. Функциональные расстройства органов пищеварения у детей. Рекомендации Общества детских гастроэнтерологов, гепатологов и нутрициологов. Часть 3. Рос вестн перинатол и педиатр. 2020;65:(6):133–144. DOI: 10.21508/1027-4065-2020-65-6-133-144. [Belmer S.V., Volynets G.V., Gorelov A.V. et al. Functional Disorders of Digestive System in Children. Guidelines of Society of Pediatric Gastroenterology, Hepatology and Nutrition. Part 3. Ros Vestn Perinatol i Pediatr. 2020;65:(6):133–144 (in Russ.)]. DOI: 10.21508/1027-4065-2020-65-6-133-144.
5. Думова Н.Б., Кручина М.К. Функциональный запор у детей разных возрастных групп. РМЖ. 2012;15:792–799. [Dumova N.B., Kruchina M.K. Functional constipation in children of different age groups. RMJ. 2012;15:792–799 (in Russ.)].
6. Файзуллина Р.А., Бельмер С.В. Хронические запоры в практике педиатра: что знаем? Что нового? Экспериментальная и клиническая гастроэнтерология. 2019;11(171):16–26. DOI: 10.31146/1682-8658-ecg-171-11-16-26. [Fayzullina R.A., Belmer S.V. Chronic constipation in pediatric practice: what do we know? Anything new? Experimental and Clinical Gastroenterology. 2019;171(11):16–26 (in Russ.)]. DOI: 10.31146/1682-8658-ecg-171-11-16-26.
7. Nellesen D., Chawla A., Oh D.L. et al. Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade. Postgrad Med. 2013;125(2):40–50. DOI: 10.3810/pgm.2013.03.2640.
8. Talley N.J., Lasch K.L., Baum C.L. A gap in our understanding: chronic constipation and its comorbid conditions. Clin Gastroenterol Hepatol. 2009;7(1):9–19. DOI: 10.1016/j.cgh.2008.07.005.
9. Choung R.S., Rey E., Schleck C.D. et al. Chronic constipation and co-morbidities: A prospective population-based nested case-control study. United European Gastroenterol J. 2016;4(1):142–151. DOI: 10.1177/2050640614558476.
10. Драпкина О.М., Шутов А.М., Ефремова Е.В. Коморбидность, мультиморбидность, двойной диагноз — синонимы или разные понятия? Кардиоваскулярная терапия и профилактика. 2019;18(2):65–69. DOI: 10.15829/17288800 2019 26569. [Drapkina O.M., Shutov A.M., Efremova E.V. Comorbidity, multimorbidity, dual diagnosis — synonyms or different terms? Cardiovascular Therapy and Prevention. 2019;18(2):65–69 (in Russ.)]. DOI: 10.15829/1728-8800-2019-2-65-69.
11. Алиева Э.И. Недержание кала у детей. Педиатрия. Журнал им. Г.Н. Сперанского. 2003;82(5):82–85. [Alieva E.I. Fecal incontinence in children. Pediatria n.a. G.N. Speransky. 2003;82(5):82–85 (in Russ.)].
12. Захарова И.Н., Бережная И.В., Шишкина С.В. Хронический запор в сочетании с дисфункцией билиарного тракта у детей: коморбидность или клиническая закономерность? Медицинский совет. 2019;(17):130–136. DOI: 10.21518/2079-701X-2019-17-130-136. [Zakharova I.N., Berezhnaya I.V., Shishkina S.V. Chronic constipation combined with biliary tract dysfunction in children: comorbidity or clinical regularity? Meditsinskiy sovet. 2019;(17):130–136 (in Russ.)]. DOI: 10.21518/2079-701X-2019-17-130-136.
13. Маевская Е.А., Маев И.В., Кучерявый Ю.А. и др. Особенности течения неалкогольного стеатогепатита, ассоциированного с хроническим запором. Экспериментальная и клиническая гастроэнтерология. 2015;9:36–44. [Mayevskaya E.A., Mayev I.V., Kucheryavyi Yu.A. et al. Features of the course of non-alcoholic steatohepatitis associated with chronic constipation. Experimental and Clinical Gastroenterology. 2015;9:36–44 (in Russ.)].
14. Козлова И.В., Лаптева Е.А. Изменения толстой кишки при неалкогольной жировой болезни печени: клинические, эндоскопические, иммуногистохимические критерии диагностики. Современные проблемы науки и образования. 2018;3:49. [Kozlova I.V., Lapteva Ye.A. Changes in the colon in non-alcoholic fatty liver disease: clinical, endoscopic, immunohistochemical diagnostic criteria. Sovremennyye problemy nauki i obrazovaniya. 2018;3:49 (in Russ.)].
15. Kessoku T., Kobayashi T., Tanaka K. et al. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci. 2021;22(15):8161. DOI: 10.3390/ijms22158161.
16. Giorgio V., Miele L., Principessa L. et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014;46(6):556–560. DOI: 10.1016/j.dld.2014.02.010.
17. Pashankar D.S., Loening-Baucke V. Increased prevalence of obesity in children with functional constipation evaluated in an academic medical center. Pediatrics. 2005;116(3):e377–e380. DOI: 10.1542/peds.
18. Hosseinzadeh S.T., Poorsaadati S., Radkani B., Forootan M. Psychological disorders in patients with chronic constipation. Gastroenterol Hepatol Bed Bench. 2011;4(3):159–163.
19. Цимбалова Е. Алгоритм лечения хронических запоров у детей. Вопросы современной педиатрии. 2011;10(3):108–113. [Tsymbalova E. Algorithm of treatment of chronic constipation in children. Current Pediatrics. 2011;10(3):108–113 (in Russ.)].
20. Ипатов А.А., Цветкова Л.Н., Полунина В.В. Факторы риска формирования и особенности течения острого и хронического запора у детей. Вопросы детской диетологии. 2014;12(3):18–22. [Ipatov A.A., Tsvetkova L.N., Polunina V.V. Risk factors for the formation and characteristics of the course of acute and chronic constipation in children. Voprosy detskoy diyetologii. 2014;12(3):18–22 (in Russ.)].
21. Волкова Л.А. Влияние функционального запора на течение угревой болезни и лечебную тактику: дис. … канд. мед. наук. М.; 2007. [Volkova L.A. The influence of functional constipation on the course of acne and therapeutic tactics: thesis. M.; 2007 (in Russ.)].
22. Huang Y.C., Wu M.C., Wang Y.H., Wei J.C. The influence of constipation on asthma: A real-world, population-based cohort study. Int J Clin Pract. 2021;75(10):e14540. DOI: 10.1111/ijcp.14540.
23. Huang Y.C., Wu M.C., Wang Y.H., Wei J.C. Influence of constipation on atopic dermatitis: A nationwide population-based cohort study in Taiwan. Int J Clin Pract. 2021;75(3):e13691. DOI: 10.1111/ijcp.13691.
24. Huang Y.C., Wu M.C., Wang Y.H., Wei J.C. Do Children With Constipation Have Increased Risk of Asthma? Real-World Data From a Nationwide Population-Based Cohort Study. Front Pediatr. 2021;9:714406. DOI: 10.3389/fped.2021.714406.
25. Nellesen D., Chawla A., Oh D.L. et al. Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade. Postgrad Med. 2013;125(2):40–50. DOI: 10.3810/pgm.2013.03.2640.
26. Беляков Д.Г., Гаус О.В., Гавриленко Д.А. Роль мукозального барьера в формировании синдрома раздраженного кишечника как потенциальной мишени для терапии заболевания. РМЖ. Медицинское обозрение. 2022;6(8):458–463. DOI: 10.32364/2587-6821-2022-6-8-458-463. [Belyakov D.G., Gaus O.V., Gavrilenko D.A. Mucosal barrier role in the formation of irritable bowel syndrome as a potential target for disease therapy. Russian Medical Inquiry. 2022;6(8):458–463 (in Russ.)]. DOI: 10.32364/2587-6821-2022-6-8-458-463.
27. Ковалева А.Л., Полуэктова Е.А., Шифрин О.С. Кишечный барьер, кишечная проницаемость, неспецифическое воспаление и их роль в формировании функциональных заболеваний желудочно-кишечного тракта. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):52–59. DOI: 10.22416/1382-4376-2020-30-4-52-59. [Kovaleva A.L., Poluektova E.A., Shifrin O.S. Intestinal Barrier, Permeability and Nonspecifi c Infl ammation in Functional Gastrointestinal Disorders. Gastroenterology, Hepatology, Coloproctology. 2020;30(4):52–59 (in Russ.)]. DOI: 10.22416/1382-4376-2020-30-4-52-59.
28. Piche T., Barbara G., Aubert P. et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196–201. DOI: 10.1136/gut.2007.140806.
29. Vancamelbeke M., Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11(9):821–834. DOI: 10.1080/17474124.2017.1343143.
30. Ардатская М.Д., Буторова Л.И., Григорьева Ю.В. и др. Клинико-метаболическая эффективность лактитола в терапии хронического запора (результаты неинтервенционной проспективной наблюдательной программы "Osmoaid"). Экспериментальная и клиническая гастроэнтерология. 2018;150(2):149–160. [Ardatskaya M.D., Butorova LI., Grigorieva Yu.V. et al. Clinical–metabolic efficiency of lactitolin the therapy of chronic constipation (results of the non-interventional prospective observation program "Osmoaid"). Experimental and Clinical Gastroenterology. 2018;150(2):149–160 (in Russ.)].
31. Pérez-Reytor D., Puebla C., Karahanian E., García K. Use of Short-Chain Fatty Acids for the Recovery of the Intestinal Epithelial Barrier Affected by Bacterial Toxins. Front Physiol. 2021;12:650313. DOI: 10.3389/fphys.2021.650313.
32. Lamprecht M., Bogner S., Schippinger G. et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr. 2012;9(1):45. DOI: 10.1186/1550-2783-9-45.
33. Карпухин О.Ю., Шакуров А.Ф., Копорулина М.О. Уровень эндотоксина как критерий оценки тяжести хронического запора и эффективности его лечения. Практическая медицина. 2014;5(81):58–61. [Karpukhin O.Yu., Shakurov A.F., Koporulina M.O. Endotoxin level as a criterion for assessing the severity of chronic constipation and the effectiveness of its treatment. Prakticheskaya meditsina. 2014;5(81):58–61 (in Russ.)].
34. Minihane A.M., Vinoy S., Russell W.R. et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr. 2015;114(7):999–1012. DOI: 10.1017/S0007114515002093.
35. Khalif I.L., Quigley E.M., Konovitch E.A., Maximova I.D. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis. 2005;37(11):838–849. DOI: 10.1016/j.dld.2005.06.008.
36. Mancabelli L., Milani C., Lugli G.А. et al. Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses. Sci Rep. 2017;7(1):9879. DOI: 10.1038/s41598-017-10663-w.
37. Zhuang M., Shang W., Ma Q. et al. Abundance of Probiotics and Butyrate-Production Microbiome Manages Constipation via Short-Chain Fatty Acids Production and Hormones Secretion. Mol Nutr Food Res. 2019;63(23):e1801187. DOI: 10.1002/mnfr.201801187.
38. Hurst N.R., Kendig D.M. et al. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. Neurogastroenterol Motil. 2014;26(11):1586–1596. DOI: 10.1111/nmo.12425.
39. Park J.H., Park D.I., Kim H.J. et al. The Relationship between Small-Intestinal Bacterial Overgrowth and Intestinal Permeability in Patients with Irritable Bowel Syndrome. Gut Liver. 2009;3(3):174–179. DOI: 10.5009/gnl.2009.3.3.174.
40. Balzan S., de Almeida Quadros C., de Cleva R. et al. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol. 2007;22(4):464–471. DOI: 10.1111/j.1440-1746.2007.04933.x.
41. Cıralı C., Ulusoy E., Kume T., Arslan N. Elevated serum neopterin levels in children with functional constipation: association with systemic proinflammatory cytokines. World J Pediatr. 2018;14(5):448–453. DOI: 10.1007/s12519-018-0144-8.
42. Sarnelli G., Aniello R.D', Pesce M. et al. Chronic constipation is a risk factor for metabolic syndrome. In: Abstracts of the 19th National Congress of Digestive Diseases. Digestive and Liver Disease. 2013;45:S131.
43. König J., Wells J., Cani P.D. et al. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. 2016;7(10):e196. DOI: 10.1038/ctg.2016.54.
44. Москалец О.В., Щербина В.И. Особенности иммунного ответа при хронических запорах у детей. Кубанский научный медицинский вестник. 2016;2(157):119–121. [Moskalets O.V., Shcherbina V.I. Features of the immune response in chronic constipation in children. Kubanskiy nauchnyy meditsinskiy vestnik. 2016;2(157):119–121 (in Russ.)].
45. Han L., Fang X., He Y. et al. ISN forefronts symposium 2015: IgA nephropathy, the gut microbiota, and gut– kidney crosstalk. Kidney International Reports. 2016;1(3):189–196. DOI: 10.1016/j.ekir.2016.08.002.
46. Лукичев Б.Г., Румянцев А.Ш., Акименко В. Микробиота кишечника и хроническая болезнь почек. Сообщение первое. Нефрология. 2018;22(4):57–73. DOI: 10.24884/1561-6274-2018-22-4-57-73. [Lukichev B.G., Rumyantsev A.Sh., Akimenko V. Colonic Microbiota And Chronic Kidney Disease. Message One. Nephrology (Saint-Petersburg). 2018;22(4):57–73 (in Russ.)]. DOI: 10.24884/1561-6274-2018-22-4-57-73.
47. Быкова С.В., Сабельникова Е.А., Новиков А.А. и др. Зонулин и I-FABP — маркеры повреждения энтероцитов при целиакии. Терапевтический архив. 2022;94(4):511–516. DOI: 10.26442/00403660.2022.04.201480. [Bykova S.V., Sabelnikova E.A., Novikov A.A. et al. Zonulin and I-FABP are markers of enterocyte damage in celiac disease. Terapevticheskii Arkhiv. 2022;94(4):511–516 (in Russ.)]. DOI: 10.26442/00403660.2022.04.201480.
48. Pelleboer R.A., Janssen R.L., Deckers-Kocken J.M. et al. Celiac disease is overrepresented in patients with constipation. J Pediatr (Rio J). 2012;88(2):173–176. DOI: 10.2223/JPED.2155.
49. Pinto-Sanchez M.I., Bercik P., Verdu E.F. Motility alterations in celiac disease and non-celiac gluten sensitivity. Dig Dis. 2015;33(2):200–207. DOI: 10.1159/000371400.
50. Husby S., Koletzko S., Korponay-Szabó I. et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr. 2020;70(1):141–156. DOI: 10.1097/MPG.0000000000002497.
51. Dehghani S.M., Basiratnia M., Matin M. et al. Urinary tract infection and enuresis in children with chronic functional constipation. Iran J Kidney Dis. 2013;7(5):363–366.
52. Stepanova N. How Advanced Is Our Understanding of the Role of Intestinal Barrier Dysfunction in the Pathogenesis of Recurrent Urinary Tract Infections. Front Pharmacol. 2022;13:780122. DOI: 10.3389/fphar.2022.780122.
53. Takano Y., Aochi Y., Ikehara S. et al. The association between constipation and subsequent risk of atopic dermatitis in children: the Japan Environment and Children's Study. Environ Health Prev Med. 2023;28:71. DOI: 10.1265/ehpm.23-00103.
54. Bowe W.P., Logan A.C. Acne vulgaris, probiotics and the gut-brain-skin axis — back to the future? Gut Pathog. 2011;3(1):1. DOI: 10.1186/1757-4749-3-1.
55. Gao M., Wang J., Liu P. et al. Gut microbiota composition in depressive disorder: a systematic review, meta-analysis, and meta-regression. Transl Psychiatry. 2023;13(1):379. DOI: 10.1038/s41398-023-02670-5.
56. Slyepchenko A., Maes M., Jacka F.N. et al. Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. Psychother Psychosom. 2017;86(1):31–46. DOI: 10.1159/000448957.
57. Motta C.R., Iêgo S., Oliveira I.T. et al. What do pediatrics residents know about the psychological factors in constipation? Psicologia, Saúde e Doenças. 2013;14(1):38–52.
58. Patil D.H., Westaby D., Mahida Y.R. et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255–259. DOI: 10.1136/gut.28.3.255.
59. Miller L.E., Tennilä J., Ouwehand A.C. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol. 2014;7:241–248. DOI: 10.2147/CEG.S58952.
60. Минушкин О.Н., Ардатская М.Д., Елизаветина Г.А. и др. Функциональные запоры: некоторые лечебные подходы. Эффективная фармакотерапия. 2011;3:29–35. [Minushkin O.N., Ardatskaya M.D., Yelizavetina G.A. et al. Functional constipation: some therapeutic approaches. Effektivnaya farmakoterapiya. 2011;3:29–35 (in Russ.)].
61. Новикова В.П. Экспортал® в лечении запоров у детей раннего возраста. Практика педиатра. 2014;5:50–52. [Novikova V.P. Exportal® in the treatment of constipation in young children. Praktika pediatra. 2014;5:50–52 (in Russ.)].
62. Martino A.M., Pesce F., Rosati U. Effetti del lattitolo nel trattamento della stasi intestinale in età pediatrica. Minerva Pediatr. 1992;44(6):319–323 (in Italian).
63. Pitzalis G., Deganello F., Mariani P. et al. Il lattitolo nella stipsi cronica idiopatica del bambino. Pediatr Med Chir. 1995;17(3):223–226 (in Italian).
64. Bonamico M., Deganello F., Mariani P. et al. Evidence of efficacy of lactitole in the treatment of chronic constipation in children. Gastroenterology. 1993;104(4):479.
65. Chen C., Li L., Wu Z. et al. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J Infect. 2007;54(1):98–102. DOI: 10.1016/j.jinf.2005.11.013.
2. Hyams J.S., di Lorenzo C., Saps M. et al. Childhood functional gastrointestinal disorders: child / adolescent. Gastroenterology. 2016:150(6):1456–1468.e2. DOI: 10.1053/j.gastro.2016.02.015.
3. Эрдес С.И., Мацукатова Б.О., Ревякина С.А. Запоры у детей (результаты нового российского популяционного исследования). РМЖ. 2011;3:159–164. [Erdes S.I., Matsukatova B.O., Revyakina S.A. Constipation in children (results of a new Russian population study). RMJ. 2011;3:159–164 (in Russ.)].
4. Бельмер С.В., Волынец Г.В., Горелов А.В. и др. Функциональные расстройства органов пищеварения у детей. Рекомендации Общества детских гастроэнтерологов, гепатологов и нутрициологов. Часть 3. Рос вестн перинатол и педиатр. 2020;65:(6):133–144. DOI: 10.21508/1027-4065-2020-65-6-133-144. [Belmer S.V., Volynets G.V., Gorelov A.V. et al. Functional Disorders of Digestive System in Children. Guidelines of Society of Pediatric Gastroenterology, Hepatology and Nutrition. Part 3. Ros Vestn Perinatol i Pediatr. 2020;65:(6):133–144 (in Russ.)]. DOI: 10.21508/1027-4065-2020-65-6-133-144.
5. Думова Н.Б., Кручина М.К. Функциональный запор у детей разных возрастных групп. РМЖ. 2012;15:792–799. [Dumova N.B., Kruchina M.K. Functional constipation in children of different age groups. RMJ. 2012;15:792–799 (in Russ.)].
6. Файзуллина Р.А., Бельмер С.В. Хронические запоры в практике педиатра: что знаем? Что нового? Экспериментальная и клиническая гастроэнтерология. 2019;11(171):16–26. DOI: 10.31146/1682-8658-ecg-171-11-16-26. [Fayzullina R.A., Belmer S.V. Chronic constipation in pediatric practice: what do we know? Anything new? Experimental and Clinical Gastroenterology. 2019;171(11):16–26 (in Russ.)]. DOI: 10.31146/1682-8658-ecg-171-11-16-26.
7. Nellesen D., Chawla A., Oh D.L. et al. Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade. Postgrad Med. 2013;125(2):40–50. DOI: 10.3810/pgm.2013.03.2640.
8. Talley N.J., Lasch K.L., Baum C.L. A gap in our understanding: chronic constipation and its comorbid conditions. Clin Gastroenterol Hepatol. 2009;7(1):9–19. DOI: 10.1016/j.cgh.2008.07.005.
9. Choung R.S., Rey E., Schleck C.D. et al. Chronic constipation and co-morbidities: A prospective population-based nested case-control study. United European Gastroenterol J. 2016;4(1):142–151. DOI: 10.1177/2050640614558476.
10. Драпкина О.М., Шутов А.М., Ефремова Е.В. Коморбидность, мультиморбидность, двойной диагноз — синонимы или разные понятия? Кардиоваскулярная терапия и профилактика. 2019;18(2):65–69. DOI: 10.15829/17288800 2019 26569. [Drapkina O.M., Shutov A.M., Efremova E.V. Comorbidity, multimorbidity, dual diagnosis — synonyms or different terms? Cardiovascular Therapy and Prevention. 2019;18(2):65–69 (in Russ.)]. DOI: 10.15829/1728-8800-2019-2-65-69.
11. Алиева Э.И. Недержание кала у детей. Педиатрия. Журнал им. Г.Н. Сперанского. 2003;82(5):82–85. [Alieva E.I. Fecal incontinence in children. Pediatria n.a. G.N. Speransky. 2003;82(5):82–85 (in Russ.)].
12. Захарова И.Н., Бережная И.В., Шишкина С.В. Хронический запор в сочетании с дисфункцией билиарного тракта у детей: коморбидность или клиническая закономерность? Медицинский совет. 2019;(17):130–136. DOI: 10.21518/2079-701X-2019-17-130-136. [Zakharova I.N., Berezhnaya I.V., Shishkina S.V. Chronic constipation combined with biliary tract dysfunction in children: comorbidity or clinical regularity? Meditsinskiy sovet. 2019;(17):130–136 (in Russ.)]. DOI: 10.21518/2079-701X-2019-17-130-136.
13. Маевская Е.А., Маев И.В., Кучерявый Ю.А. и др. Особенности течения неалкогольного стеатогепатита, ассоциированного с хроническим запором. Экспериментальная и клиническая гастроэнтерология. 2015;9:36–44. [Mayevskaya E.A., Mayev I.V., Kucheryavyi Yu.A. et al. Features of the course of non-alcoholic steatohepatitis associated with chronic constipation. Experimental and Clinical Gastroenterology. 2015;9:36–44 (in Russ.)].
14. Козлова И.В., Лаптева Е.А. Изменения толстой кишки при неалкогольной жировой болезни печени: клинические, эндоскопические, иммуногистохимические критерии диагностики. Современные проблемы науки и образования. 2018;3:49. [Kozlova I.V., Lapteva Ye.A. Changes in the colon in non-alcoholic fatty liver disease: clinical, endoscopic, immunohistochemical diagnostic criteria. Sovremennyye problemy nauki i obrazovaniya. 2018;3:49 (in Russ.)].
15. Kessoku T., Kobayashi T., Tanaka K. et al. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci. 2021;22(15):8161. DOI: 10.3390/ijms22158161.
16. Giorgio V., Miele L., Principessa L. et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014;46(6):556–560. DOI: 10.1016/j.dld.2014.02.010.
17. Pashankar D.S., Loening-Baucke V. Increased prevalence of obesity in children with functional constipation evaluated in an academic medical center. Pediatrics. 2005;116(3):e377–e380. DOI: 10.1542/peds.
18. Hosseinzadeh S.T., Poorsaadati S., Radkani B., Forootan M. Psychological disorders in patients with chronic constipation. Gastroenterol Hepatol Bed Bench. 2011;4(3):159–163.
19. Цимбалова Е. Алгоритм лечения хронических запоров у детей. Вопросы современной педиатрии. 2011;10(3):108–113. [Tsymbalova E. Algorithm of treatment of chronic constipation in children. Current Pediatrics. 2011;10(3):108–113 (in Russ.)].
20. Ипатов А.А., Цветкова Л.Н., Полунина В.В. Факторы риска формирования и особенности течения острого и хронического запора у детей. Вопросы детской диетологии. 2014;12(3):18–22. [Ipatov A.A., Tsvetkova L.N., Polunina V.V. Risk factors for the formation and characteristics of the course of acute and chronic constipation in children. Voprosy detskoy diyetologii. 2014;12(3):18–22 (in Russ.)].
21. Волкова Л.А. Влияние функционального запора на течение угревой болезни и лечебную тактику: дис. … канд. мед. наук. М.; 2007. [Volkova L.A. The influence of functional constipation on the course of acne and therapeutic tactics: thesis. M.; 2007 (in Russ.)].
22. Huang Y.C., Wu M.C., Wang Y.H., Wei J.C. The influence of constipation on asthma: A real-world, population-based cohort study. Int J Clin Pract. 2021;75(10):e14540. DOI: 10.1111/ijcp.14540.
23. Huang Y.C., Wu M.C., Wang Y.H., Wei J.C. Influence of constipation on atopic dermatitis: A nationwide population-based cohort study in Taiwan. Int J Clin Pract. 2021;75(3):e13691. DOI: 10.1111/ijcp.13691.
24. Huang Y.C., Wu M.C., Wang Y.H., Wei J.C. Do Children With Constipation Have Increased Risk of Asthma? Real-World Data From a Nationwide Population-Based Cohort Study. Front Pediatr. 2021;9:714406. DOI: 10.3389/fped.2021.714406.
25. Nellesen D., Chawla A., Oh D.L. et al. Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade. Postgrad Med. 2013;125(2):40–50. DOI: 10.3810/pgm.2013.03.2640.
26. Беляков Д.Г., Гаус О.В., Гавриленко Д.А. Роль мукозального барьера в формировании синдрома раздраженного кишечника как потенциальной мишени для терапии заболевания. РМЖ. Медицинское обозрение. 2022;6(8):458–463. DOI: 10.32364/2587-6821-2022-6-8-458-463. [Belyakov D.G., Gaus O.V., Gavrilenko D.A. Mucosal barrier role in the formation of irritable bowel syndrome as a potential target for disease therapy. Russian Medical Inquiry. 2022;6(8):458–463 (in Russ.)]. DOI: 10.32364/2587-6821-2022-6-8-458-463.
27. Ковалева А.Л., Полуэктова Е.А., Шифрин О.С. Кишечный барьер, кишечная проницаемость, неспецифическое воспаление и их роль в формировании функциональных заболеваний желудочно-кишечного тракта. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):52–59. DOI: 10.22416/1382-4376-2020-30-4-52-59. [Kovaleva A.L., Poluektova E.A., Shifrin O.S. Intestinal Barrier, Permeability and Nonspecifi c Infl ammation in Functional Gastrointestinal Disorders. Gastroenterology, Hepatology, Coloproctology. 2020;30(4):52–59 (in Russ.)]. DOI: 10.22416/1382-4376-2020-30-4-52-59.
28. Piche T., Barbara G., Aubert P. et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196–201. DOI: 10.1136/gut.2007.140806.
29. Vancamelbeke M., Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11(9):821–834. DOI: 10.1080/17474124.2017.1343143.
30. Ардатская М.Д., Буторова Л.И., Григорьева Ю.В. и др. Клинико-метаболическая эффективность лактитола в терапии хронического запора (результаты неинтервенционной проспективной наблюдательной программы "Osmoaid"). Экспериментальная и клиническая гастроэнтерология. 2018;150(2):149–160. [Ardatskaya M.D., Butorova LI., Grigorieva Yu.V. et al. Clinical–metabolic efficiency of lactitolin the therapy of chronic constipation (results of the non-interventional prospective observation program "Osmoaid"). Experimental and Clinical Gastroenterology. 2018;150(2):149–160 (in Russ.)].
31. Pérez-Reytor D., Puebla C., Karahanian E., García K. Use of Short-Chain Fatty Acids for the Recovery of the Intestinal Epithelial Barrier Affected by Bacterial Toxins. Front Physiol. 2021;12:650313. DOI: 10.3389/fphys.2021.650313.
32. Lamprecht M., Bogner S., Schippinger G. et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr. 2012;9(1):45. DOI: 10.1186/1550-2783-9-45.
33. Карпухин О.Ю., Шакуров А.Ф., Копорулина М.О. Уровень эндотоксина как критерий оценки тяжести хронического запора и эффективности его лечения. Практическая медицина. 2014;5(81):58–61. [Karpukhin O.Yu., Shakurov A.F., Koporulina M.O. Endotoxin level as a criterion for assessing the severity of chronic constipation and the effectiveness of its treatment. Prakticheskaya meditsina. 2014;5(81):58–61 (in Russ.)].
34. Minihane A.M., Vinoy S., Russell W.R. et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr. 2015;114(7):999–1012. DOI: 10.1017/S0007114515002093.
35. Khalif I.L., Quigley E.M., Konovitch E.A., Maximova I.D. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis. 2005;37(11):838–849. DOI: 10.1016/j.dld.2005.06.008.
36. Mancabelli L., Milani C., Lugli G.А. et al. Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses. Sci Rep. 2017;7(1):9879. DOI: 10.1038/s41598-017-10663-w.
37. Zhuang M., Shang W., Ma Q. et al. Abundance of Probiotics and Butyrate-Production Microbiome Manages Constipation via Short-Chain Fatty Acids Production and Hormones Secretion. Mol Nutr Food Res. 2019;63(23):e1801187. DOI: 10.1002/mnfr.201801187.
38. Hurst N.R., Kendig D.M. et al. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. Neurogastroenterol Motil. 2014;26(11):1586–1596. DOI: 10.1111/nmo.12425.
39. Park J.H., Park D.I., Kim H.J. et al. The Relationship between Small-Intestinal Bacterial Overgrowth and Intestinal Permeability in Patients with Irritable Bowel Syndrome. Gut Liver. 2009;3(3):174–179. DOI: 10.5009/gnl.2009.3.3.174.
40. Balzan S., de Almeida Quadros C., de Cleva R. et al. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol. 2007;22(4):464–471. DOI: 10.1111/j.1440-1746.2007.04933.x.
41. Cıralı C., Ulusoy E., Kume T., Arslan N. Elevated serum neopterin levels in children with functional constipation: association with systemic proinflammatory cytokines. World J Pediatr. 2018;14(5):448–453. DOI: 10.1007/s12519-018-0144-8.
42. Sarnelli G., Aniello R.D', Pesce M. et al. Chronic constipation is a risk factor for metabolic syndrome. In: Abstracts of the 19th National Congress of Digestive Diseases. Digestive and Liver Disease. 2013;45:S131.
43. König J., Wells J., Cani P.D. et al. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. 2016;7(10):e196. DOI: 10.1038/ctg.2016.54.
44. Москалец О.В., Щербина В.И. Особенности иммунного ответа при хронических запорах у детей. Кубанский научный медицинский вестник. 2016;2(157):119–121. [Moskalets O.V., Shcherbina V.I. Features of the immune response in chronic constipation in children. Kubanskiy nauchnyy meditsinskiy vestnik. 2016;2(157):119–121 (in Russ.)].
45. Han L., Fang X., He Y. et al. ISN forefronts symposium 2015: IgA nephropathy, the gut microbiota, and gut– kidney crosstalk. Kidney International Reports. 2016;1(3):189–196. DOI: 10.1016/j.ekir.2016.08.002.
46. Лукичев Б.Г., Румянцев А.Ш., Акименко В. Микробиота кишечника и хроническая болезнь почек. Сообщение первое. Нефрология. 2018;22(4):57–73. DOI: 10.24884/1561-6274-2018-22-4-57-73. [Lukichev B.G., Rumyantsev A.Sh., Akimenko V. Colonic Microbiota And Chronic Kidney Disease. Message One. Nephrology (Saint-Petersburg). 2018;22(4):57–73 (in Russ.)]. DOI: 10.24884/1561-6274-2018-22-4-57-73.
47. Быкова С.В., Сабельникова Е.А., Новиков А.А. и др. Зонулин и I-FABP — маркеры повреждения энтероцитов при целиакии. Терапевтический архив. 2022;94(4):511–516. DOI: 10.26442/00403660.2022.04.201480. [Bykova S.V., Sabelnikova E.A., Novikov A.A. et al. Zonulin and I-FABP are markers of enterocyte damage in celiac disease. Terapevticheskii Arkhiv. 2022;94(4):511–516 (in Russ.)]. DOI: 10.26442/00403660.2022.04.201480.
48. Pelleboer R.A., Janssen R.L., Deckers-Kocken J.M. et al. Celiac disease is overrepresented in patients with constipation. J Pediatr (Rio J). 2012;88(2):173–176. DOI: 10.2223/JPED.2155.
49. Pinto-Sanchez M.I., Bercik P., Verdu E.F. Motility alterations in celiac disease and non-celiac gluten sensitivity. Dig Dis. 2015;33(2):200–207. DOI: 10.1159/000371400.
50. Husby S., Koletzko S., Korponay-Szabó I. et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr. 2020;70(1):141–156. DOI: 10.1097/MPG.0000000000002497.
51. Dehghani S.M., Basiratnia M., Matin M. et al. Urinary tract infection and enuresis in children with chronic functional constipation. Iran J Kidney Dis. 2013;7(5):363–366.
52. Stepanova N. How Advanced Is Our Understanding of the Role of Intestinal Barrier Dysfunction in the Pathogenesis of Recurrent Urinary Tract Infections. Front Pharmacol. 2022;13:780122. DOI: 10.3389/fphar.2022.780122.
53. Takano Y., Aochi Y., Ikehara S. et al. The association between constipation and subsequent risk of atopic dermatitis in children: the Japan Environment and Children's Study. Environ Health Prev Med. 2023;28:71. DOI: 10.1265/ehpm.23-00103.
54. Bowe W.P., Logan A.C. Acne vulgaris, probiotics and the gut-brain-skin axis — back to the future? Gut Pathog. 2011;3(1):1. DOI: 10.1186/1757-4749-3-1.
55. Gao M., Wang J., Liu P. et al. Gut microbiota composition in depressive disorder: a systematic review, meta-analysis, and meta-regression. Transl Psychiatry. 2023;13(1):379. DOI: 10.1038/s41398-023-02670-5.
56. Slyepchenko A., Maes M., Jacka F.N. et al. Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. Psychother Psychosom. 2017;86(1):31–46. DOI: 10.1159/000448957.
57. Motta C.R., Iêgo S., Oliveira I.T. et al. What do pediatrics residents know about the psychological factors in constipation? Psicologia, Saúde e Doenças. 2013;14(1):38–52.
58. Patil D.H., Westaby D., Mahida Y.R. et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255–259. DOI: 10.1136/gut.28.3.255.
59. Miller L.E., Tennilä J., Ouwehand A.C. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol. 2014;7:241–248. DOI: 10.2147/CEG.S58952.
60. Минушкин О.Н., Ардатская М.Д., Елизаветина Г.А. и др. Функциональные запоры: некоторые лечебные подходы. Эффективная фармакотерапия. 2011;3:29–35. [Minushkin O.N., Ardatskaya M.D., Yelizavetina G.A. et al. Functional constipation: some therapeutic approaches. Effektivnaya farmakoterapiya. 2011;3:29–35 (in Russ.)].
61. Новикова В.П. Экспортал® в лечении запоров у детей раннего возраста. Практика педиатра. 2014;5:50–52. [Novikova V.P. Exportal® in the treatment of constipation in young children. Praktika pediatra. 2014;5:50–52 (in Russ.)].
62. Martino A.M., Pesce F., Rosati U. Effetti del lattitolo nel trattamento della stasi intestinale in età pediatrica. Minerva Pediatr. 1992;44(6):319–323 (in Italian).
63. Pitzalis G., Deganello F., Mariani P. et al. Il lattitolo nella stipsi cronica idiopatica del bambino. Pediatr Med Chir. 1995;17(3):223–226 (in Italian).
64. Bonamico M., Deganello F., Mariani P. et al. Evidence of efficacy of lactitole in the treatment of chronic constipation in children. Gastroenterology. 1993;104(4):479.
65. Chen C., Li L., Wu Z. et al. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J Infect. 2007;54(1):98–102. DOI: 10.1016/j.jinf.2005.11.013.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
